Abstract: Tildrakizumab, a high-affinity humanized IgG1k antibody that selectively binds interleukin (IL)-23 p19 subunit of cytokine IL-23 and neutralizes its function, is under investigation for treatment of moderate-to-severe chronic plaque psoriasis. The objective of this analysis was to assess the pharmacokinetics, bioavailability and safety/tolerability of single ascending doses of tildrakizumab after intravenous (IV) and subcutaneous (SC) dosing in healthy subjects. P05661 was a phase 1, single-dose, randomized, placebo-controlled study of tildrakizumab IV doses of 0.1, 0.5, 3 and 10 mg/kg, or placebo. P05776 was a phase 1, single-dose, randomized, placebo-controlled study of tildrakizumab SC doses of 50 or 200 mg, or placebo. After either single IV or SC dosing, tildrakizumab exhibited slow systemic clearance (CL), limited volume of distribution and a long t 1/2 . Both the C max and the area under the curve (AUC) increased proportionally with doses from 0.1 to 10 mg/kg, or 50-200 mg. The bioavailability of SC dosing was~80% (90% CI: 62-103%) for 50 mg and~73% (90% CI: 46-115%) for 200 mg, respectively, versus 0.5 and 3 mg/kg IV. Across both studies, six of 43 evaluable subjects were positive for post-dose antidrug antibodies; two of these were positive for neutralizing antibodies. Most adverse events (AEs) were mild; the most frequent AEs included upper respiratory tract infection and headache. Single doses of tildrakizumab 0.1, 0.5, 3 and 10 mg/kg administered IV or single doses of 50 and 200 mg administered SC were safe and well tolerated in healthy adult subjects.
Psoriasis is a debilitating chronic inflammatory autoimmune skin disease characterized by red, scaly skin plaques frequently occurring in areas of the body that are susceptible to trauma (e.g. elbows and knees) [1] . The development of psoriasis is influenced by both genetic and geographic predispositions, with an estimated worldwide prevalence of 2-3% [2] . The current treatments for moderate-to-severe psoriasis include topical therapy and phototherapy as well as systemic small molecule and biologic therapies; however, patient satisfaction remains low and many patients remain undertreated [3, 4] . Therefore, a significant unmet clinical need remains for effective psoriasis therapies across the globe.
The successful treatment of psoriasis through targeting of tumour necrosis factor (TNF)-a inhibitors (infliximab, adalimumab, etanercept) confirmed that there is an immunemediated pathogenesis associated with this chronic skin disease [5] . The search for more targeted psoriasis therapies led to the development of additional anticytokine therapies, such as monoclonal antibodies that target the p40 subunit of interleukin (IL)-12/IL-23 (ustekinumab) [6] . However, subsequent research identified that IL-23-dependent T helper (Th) 17 cells, rather than IL-12-dependent Th1 cells, perpetuate much of the inflammatory cascade underlying psoriasis [7, 8] . These data suggest that psoriasis is driven primarily by IL-23 and is associated with downstream inflammatory molecules such as IL-17A and IL-22 rather than IL-12 [9] . IL-23 is a heterodimer, and the first subunit (p40) is shared between IL-12 and IL-23. The second subunit (p19) is specific to IL-23. Specific targeting of the IL-23 (guselkumab) and IL-17 (secukinumab, ixekizumab, brodalumab) inflammatory pathways has become an effective therapeutic approach for psoriasis [9, 10] .
Tildrakizumab (MK-3222) is a high-affinity humanized immunoglobulin G1/k monoclonal antibody that specifically binds the p19 subunit of human IL-23 and has been approved for the treatment of moderate-to-severe chronic plaque psoriasis. A phase 1, randomized, placebo-controlled, proof-of-concept study showed that tildrakizumab doses of 0.05-10 mg/kg administered intravenously (IV) produced clinical improvement in patients with psoriasis [11] .
Further, a phase 2b, randomized, double-blind, placebo-controlled study showed that subcutaneous (SC) administration of tildrakizumab at doses of 100 and 200 mg produced clinical improvement in psoriasis symptoms over 52 weeks of treatment. Upon cessation of treatment, a low rate of relapse was seen during a 20-week non-treatment period in the phase 2b study [12] . In two additional three-part, parallel group, double-blind, randomized, controlled phase 3 trials, tildrakizumab was shown to be efficacious and well tolerated for the treatment of chronic plaque psoriasis [13] . Taken together, these results show the utility of monoclonal antibodies that selectively target IL-23p19 and therefore the IL-23/17 axis in the treatment of psoriasis.
This report describes the results of two phase 1 studies designed to investigate the pharmacokinetics (PK) of tildrakizumab in healthy subjects. The objectives of these studies were as follows: (i) to determine the safety, tolerability and PK of ascending single IV doses (P05661) or ascending single SC fixed doses (P05776) of tildrakizumab in healthy subjects; (ii) to compare the relative bioavailability across two studies, an ascending single SC dose of tildrakizumab versus an ascending single IV dose in healthy subjects; and (iii) to assess the effects of tildrakizumab on biomarkers of the IL-23 pathway in healthy subjects. Calprotectin was also monitored as a potentially useful clinical inflammatory marker.
Methods
Subjects. In both studies, healthy male and female subjects between the ages of 18 and 45 years belonging to any race or ethnic background were eligible for enrolment. Major exclusion criteria included a history of clinically significant diseases (including hepatitis B, hepatitis C and HIV), use of a systemic immunosuppressive agent within 4 weeks of treatment or exposure to anti-IL-12/23 p40 antibodies at any point in time.
Study designs. The trial protocols (P05661 and P05776; sponsor Merck & Co., Inc., Kenilworth, NJ, USA) were approved by the appropriate ethics review committee (The Alfred Human Research Ethics Committee, Melbourne, Australia, for both studies). These trials were conducted in accordance with the guidelines on Good Clinical Practice and with the ethical standards for human experimentation established by the Declaration of Helsinki. All subjects provided written informed consent prior to participating in the trial. Both studies were conducted at a single trial centre located in Melbourne, Australia. Study P05661 was conducted between the dates of 17 October 2008 and 17 June 2010. Study P05776 was conducted between the dates of 19 June 2009 and 25 March 2010. These studies were not required to be registered on clinicaltrials.gov as they were phase 1 clinical investigations and therefore did not meet the FDAAA 801 definition of an 'applicable clinical trial'.
In P05661 (Data S1), a total of 29 subjects were randomized to receive a single ascending IV dose of tildrakizumab or matching placebo (normal saline) in a 3:1 ratio across dose groups of 0.1, 0.5, 3 and 10 mg/kg. Subjects fasted after midnight on the day of dosing and received a single IV infusion of tildrakizumab or placebo over a period of 1 hr. Serum PK samples were obtained pre-dose, and at 2, 6, 12, 24 and 48 hr after dosing and on days 7, 14, 28, 42, 56, 70, 84, 91, 112, 140, 168 and 196 . Serum samples for antidrug antibodies (ADA) were collected pre-dose and at the same time as PK samples from days 7 through 196. Serum samples for total IL-23 were collected at the same time-points as for PK. Biomarker serum samples for IL-22 and calprotectin were collected pre-dose, 24 hr after dosing and on days 7, 14, 42, 70, 91, 140, 168 and 196. In P05776 (Data S2), a total of 37 subjects were randomized to receive a single SC dose of tildrakizumab or matching placebo (normal saline) in a 3:1 ratio across dose groups of 50 and 200 mg. In P05776, subjects fasted overnight before receiving the first dose. Subjects received tildrakizumab or matching placebo administered as a single SC injection on Day 1 for the 50 mg (0.5 mL) dose or two SC injections (1 mL each) on Day 1 for the 200 mg dose. The tildrakizumab formulation was 100 mg/mL. Tildrakizumab or placebo was administered in the following anatomical areas: abdomen, upper arms or upper thighs. Serum PK samples were obtained pre-dose, and at 2, 6, 12, 24, 48 and 72 hr after dosing and on days 7, 14, 28, 42, 56, 70, 84, 112 and 140. Serum samples for ADA were collected pre-dose and at the same time as PK samples from days 7 through 140. Serum samples for total IL-23 were collected at the same time-points as for PK. Biomarker serum samples for IL-22 and calprotectin were collected pre-dose, 24 hr after dosing and on days 4, 7, 28, 56, 84, 112 and 140.
Adverse events (AEs) were monitored throughout both studies. Injection sites in P05776 were inspected for tenderness, erythema, swelling, induration, purulence or frank vein thrombosis at the site. Blood was collected for evaluation of clinical laboratory safety parameters. For both studies, other safety assessments were performed throughout, including vital signs and electrocardiograms. Concomitant medications and AEs were recorded. The subject's last visit was scheduled on the day of the subject's last safety and PK assessments.
Analytical methods. Blood samples were collected throughout the study for the assessment of drug concentrations, ADA and biomarkers. Blood samples were allowed to remain upright at room temperature for 30 min. to clot, then placed in a refrigerated centrifuge (4°C) and centrifuged for 15 min. at 1500 9 g. All serum samples were frozen within 30 min. of aliquoting at À70°C or colder and maintained in the frozen state until assayed. Samples were transferred to the appropriate analytical site on dry ice. Serum assays for tildrakizumab, ADA and IL-23 concentrations were performed by Schering Plough Research Institute (Kenilworth, NJ, USA) using validated electrochemiluminescence assays on the MSD sector imager 6000 analyser (MSD, Rockville, MD, USA). The LLOQ (lower limit of quantification) for the tildrakizumab assay was 3.13 ng/mL. The accuracy of the tildrakizumab assay was À13.7% to 12.2% (intra-assay) and À3.6% to 4.6% (inter-assay). The precision of the tildrakizumab assay was ≤12.7% [intra-assay, % coefficient of variation (CV)] and ≤8.4% (inter-assay, CV%).
The LLOQ for the ADA assay was 15.0 ng/mL. The LLOQ for IL-23 was 20 pg/mL. Serum samples for IL-22 and calprotectin concentrations were analysed by Medpace Reference Laboratories (Cincinnati, OH, USA) using a quantitative sandwich enzyme immunoassay technique (ELISA) from R&D Systems (Minneapolis, MN, USA) with an LLOQ of 2.7 pg/mL and Hycult Biotechnology (Plymouth Meeting, PA, USA) with an LLOQ of 1.6 ng/mL, respectively.
Data analysis and statistical methods. Pharmacokinetic parameters of interest in both studies included area under the concentration-time curve from time zero to last time-point (AUC 0-last ), maximum concentration (C max ) and time to maximum concentration (T max ). Additional parameters, such as area under the concentration-time curve from time zero to infinity (AUC 0-∞ ), apparent terminal half-life (t 1/2 ), clearance (CL; P05661 only) and volume of distribution (V d ; P05661 only), relative bioavailability (F; P05776, only), apparent volume of distribution (V d /F; P05776, only) and apparent total body clearance (CL/F; P05776, only), also were calculated and summarized by dose.
Immunogenicity was summarized using the ADA assay results from each subject's time-points collected before and after treatment with tildrakizumab. Samples that were positive in the ADA assay were tested for neutralizing ADA.
For P05661, dose proportionality was assessed using a power law model with ln(PK parameter) as the dependent variable and ln(dose) as an explanatory variable. Point estimates of the slope associated with ln(dose) together with the 95% CI were calculated. A slope of 1 was considered consistent with dose proportionality. Dose proportionality in P05776 was estimated based on the arithmetic means of AUC 0-∞ and C max .
The relative bioavailability of a single SC dose for 50 mg or 200 mg was estimated through a cross-study comparison to a single IV dose using AUC 0-∞ dose normalized to 1 mg/kg. Based on an ANOVA model extracting effects due to dose, the geometric mean ratios (GMR) with the 90% CI of the comparisons of 50 mg SC versus 0.5 mg/kg IV and 200 mg SC versus 3 mg/kg IV were calculated.
In both studies, safety and biomarker data for subjects receiving placebo were pooled across cohorts.
Results

Study population.
In study P05661, 29 healthy adult subjects (11 men and 18 women) aged 18-44 years (mean, 26.3 years) were randomized to tildrakizumab (n = 4, 0.1 mg/kg; n = 4, 0.5 mg/kg; n = 8, 3 mg/kg; n = 6, 10 mg/kg) or placebo (n = 7). Of these, 25 (86%) were Caucasian, three (10%) were Asian and one (3%) was native Hawaiian or other Pacific Islander (Table S1 ). A total of 22 subjects completed the study and seven discontinued study drug for the following reasons: n = 4, withdrawal of consent (one was not dosed, others discontinued at days 6, 12 and 98); n = 2, lost to follow-up (at days 8 and 92); and n = 1, AE (pregnancy, discontinued at Day 380).
In study P05776, 37 healthy adult subjects (23 men and 14 women) aged 18-45 years (mean, 26.5 years) were randomized to tildrakizumab or placebo. Of these, 27 (73%) were Caucasian, nine (24%) were Asian and one (3%) was Multiracial (Table S2) . A total of 18 subjects were enrolled in Cohort 1 (n = 14 tildrakizumab 50 mg and n = 4 placebo) and 19 in Cohort 2 (n = 14 tildrakizumab 200 mg and n = 5 placebo). A total of 31 subjects were treated (six discontinued before receiving study drug), with 25 completing the treatment phase as planned. Another six subjects discontinued after receiving treatment for the following reasons: n = 4, withdrawal of consent (discontinued at days 11, 63, 81, 84); n = 2, lost to follow-up (days 71 and 91). After IV administration in P05661, both the C max and AUC 0-∞ of tildrakizumab increased proportionally with dose over a range from 0.1 to 10 mg/kg (table 3 and fig. 3 , and additionally, Figure S1 for AUC 0-last and Figure S2 for C max ).
The estimated slopes for C max , AUC 0-last and AUC 0-∞ were 0.99 (95% CI: 0.96-1.02), 1.02 (95% CI: 0.97-1.07) and 1.02 (95% CI: 0.96-1.07), respectively. The 95% CIs for each PK parameter included 1.0, suggestive of dose proportionality (table 3) .
After IV administration, the mean t 1/2 values were 29.4, 29.7, 26.9 and 24.6 days at 0.1, 0.5, 3 and 10 mg/kg doses, respectively (table 1). The mean CL after a single IV administration of tildrakizumab was independent of dose and ranged from 2.04 to 2.52 mL/day/kg. The mean V d ranged from 76.9 to 106 mL/kg and was independent of dose. These findings suggest a limited volume of distribution of tildrakizumab. The variability of the IV pharmacokinetic parameters of AUC 0-∞ and C max was low to moderate, CV% ranged from 5% to 25% and 4% to 9 %, respectively.
After SC administration in P05776, the PK of tildrakizumab appeared to increase proportionally with dose from 50 to 200 mg (table 2) . Both AUC 0-∞ and C max increased by~4 times with a four-time increase in dose. The mean t 1/2 was 25.1 and 24.5 days for the 50 and 200 mg doses, respectively. The variability of SC pharmacokinetic parameters of AUC 0-∞ and C max was moderate, CV% ranged from 21% to 47% and 26% to 38%, respectively.
In a cross-study comparison between P05661 and P05776, the bioavailability of tildrakizumab after a single SC dose of 50 mg or 200 mg, based on the GMR of AUC 0-∞ dose normalized to 1 mg/kg, was estimated to be~80% (90% CI: 62-103%) and~73% (90% CI: 46-115%), respectively, relative to 0.5 and 3 mg/kg IV doses, respectively, as shown in table 4.
Immunogenicity results.
In study P05661 after tildrakizumab administration, two subjects tested positive for ADA of 21 evaluable subjects (one subject each in the 3 and 10 mg/kg groups). Both subjects had at least one post-dose sample that was positive for neutralizing antibodies. The terminal half-life of tildrakizumab was decreased in these two subjects (10.1 and 13.5 days) as compared to the range of mean values (26.8-32.4 days) in the PK analysis population, after exclusion of these two post-dose positive subjects. In addition, three subjects treated with tildrakizumab had baseline samples that tested positive for ADA, but showed no post-dose positive samples and no effects on PK.
In study P05776 after tildrakizumab administration, four subjects tested positive for ADA of 22 evaluable subjects (two in each of the 50 and 20 mg groups). None had neutralizing antibodies. Antibody development appeared to have minimal to no influence on the PK profile of tildrakizumab in these four subjects. In addition, one subject treated with tildrakizumab had a baseline sample that tested positive for ADA, but showed no post-dose positive samples and no effects on PK.
Pharmacodynamic results.
In general, IL-23 and IL-22 levels were below the limit of quantification (LLOQ; 20 pg/mL for IL-23 and 2.7 pg/mL for IL-22) both pre-and post-dose in most subjects enrolled in these studies.
In both P05661 and P05776, serum calprotectin was detectable in all subjects; mean baseline values ranged from 386 to 982 ng/mL. No clear trends were seen between baseline values and post-tildrakizumab treatment values or with any dose of tildrakizumab.
Safety results.
In study P05661, 24 (83%) subjects reported at least one AE during the study: two (50%) subjects in the 0.1 mg/kg group, four (100%) subjects in the 0.5 mg/kg group, seven (88%) subjects in the 3 mg/kg group, six (100%) subjects in the 10 mg/kg group and five (71%) subjects in the placebo group. The most common AEs across all treatments, including placebo, were upper respiratory tract infection (n = 11), headache (n = 8), vessel puncture site haematoma (n = 4), lethargy (n = 3), pharyngitis (n = 3), dysmenorrhoea (n = 2), nasopharyngitis (n = 2), nausea (n = 2), rhinitis (n = 2) and seasonal allergy (n = 2). Serious AEs (SAEs) occurred in one subject on placebo (surgery for upper airway obstruction and rhinitis) and one subject on tildrakizumab 10 mg/kg (hospitalized for pyrexia due to chikungunya virus infection). Neither of these SAEs was considered related to treatment by the investigator. Severe AEs were reported in three subjects: one subject with an AE of chikungunya virus in the 10 mg/kg group (as reported above), one subject with an AE of viral gastritis in the 10 mg/kg group and one subject with an AE of pharyngitis in the 0.5 mg/kg group. None of these severe AEs were considered related to study treatment by the study investigator. Of the 29 subjects randomized, five (17%) subjects reported at least one treatment-emergent AE that was considered possibly or likely treatment-related. The most frequent treatment-related treatment-emergent AEs were headache (n = 3) and upper respiratory tract infection (n = 2). One AE of infusion-related reaction was reported by a subject in the 3 mg/kg group who reported a cold sensation at the infusion site that was considered possibly drug-related by the study investigator. All AEs were resolved. There were no dose-related trends observed in the overall frequencies or types of AEs. No subject died during the study. Both subjects who tested positive for ADA after dosing with tildrakizumab reported AEs at study times when ADA were detectable (upper respiratory tract infection, presyncope, ear infection and chikungunya virus infection); however, they were not suggestive of safety concerns related to immunogenicity.
In study P05776, 24 (65%) subjects reported at least one AE during the study: nine (64%) subjects in the 50 mg group, eight (57%) subjects in the 200 mg group and seven (78%) subjects in the placebo group. The most common AEs across all treatment groups, including placebo, were upper respiratory tract infection (n = 12) and headache (n = 10). AEs reported in two or more subjects included upper respiratory tract infection (n = 12), headache (n = 10), acne (n = 2), gastroenteritis (n = 2), injection site erythema (n = 2), insomnia (n = 2), migraine (n = 2), rhinitis allergic (n = 2) and rash (n = 2). No SAEs were reported in this study. Two subjects in the 50 mg group reported three severe AEs [headache and drug hypersensitivity to a concomitant medication (n = 1), viral gastroenteritis (n = 1)] that were considered by the study investigator to AUC 0-last , area under the concentration-time curve from time 0 to the time of the last quantifiable sample; AUC 0-1 , area under the concentrationtime curve from time 0 to infinity; CL, clearance; CV, coefficient of variation; IV, intravenous. 1 T max = Median (range). 2 N = 3 (excluded one subject due to discontinuation). 3 N = 4 (excluded two subjects due to discontinuation). be unlikely related to study treatment, and one subject in the placebo group reported a severe AE (migraine) that was considered unlikely related to study treatment. There were no severe AEs in the 200 mg group. There were no dose-related trends observed in the overall frequencies or types of AEs. No subject died during the study. Injection site inspections resulted in findings of mild reactions ('erythema only' or 'tender site or erythema') in two subjects receiving 200 mg of tildrakizumab and two subjects receiving placebo. No findings were reported later than Day 2. There were no findings of injection site AEs in the 50 mg group. For the four subjects in which ADA were detected after administration of tildrakizumab, one subject did not report any AEs. The other three subjects with post-dose positive samples reported AEs, which
were not suggestive of immunogenicity-related safety concerns (upper respiratory tract infection, seasonal allergy, pain in extremity and headache). No clinically meaningful trends in blood chemistry or haematological parameters, vital signs or electrocardiograms were observed during any treatment in either of the studies.
Discussion
Tildrakizumab is an IL-23p19 monoclonal antibody approved for the treatment of chronic plaque psoriasis. Tildrakizumab was demonstrated to improve the signs and symptoms of psoriasis and was generally well tolerated [12, 13] . These trials were conducted to assess the PK, safety/tolerability and relative bioavailability of single ascending doses of tildrakizumab administered either via IV (P05661) or SC injection (P05776) in healthy adult subjects.
Single doses of tildrakizumab 0.1, 0.5, 3 and 10 mg/kg administered IV over 1 hr and doses of 50 and 200 mg administered by SC injection were generally well tolerated in healthy subjects. The most common AEs were respiratory infection and headache in both studies. Most AEs were mild to moderate in severity. The overall incidence of treatmentemergent AEs did not show marked dose dependence in either study. None of the AEs reported by the six subjects testing positive for ADA after tildrakizumab dosing were suggestive of any safety concerns due to immunogenicity. In addition, no clinically meaningful changes in blood chemistry, haematological parameters, vital signs or electrocardiograms were seen in any treatment group.
Typical for monoclonal antibodies, after either single IV infusion or SC administration, tildrakizumab exhibited slow systemic CL (0.143-0.176 L/day using 70 kg body-weight, table 1), limited volume of distribution (5.4-7.4 L via noncompartmental analysis and 70 kg weight, table 1) and a long t 1/2 (24.5-29.4 days, tables 1 and 2). These parameters are similar to those discussed in reviews of the population PK of monoclonal antibodies [14, 15] [14, 16] . The variability in tildrakizumab AUC 0-∞ was low to moderate AUC 0-∞ , area under the concentration-time curve from time 0 to infinity; AUC 0-last , area under the concentration-time curve from time 0 to the time of the last quantifiable sample; CI, confidence interval; CL/F, apparent total body clearance; C max , maximum observed serum concentration; CV, coefficient of variation; F, relative bioavailability; n, number of subjects; SC, subcutaneous; t 1/2 , terminal phase half-life; T max , time to maximum observed serum concentration; V d /F, apparent volume of distribution. 1 T max = Median (range). 2 N = 9 (excluded two subjects due to discontinuation). 3 N = 10 (excluded one subject due to discontinuation). [19] and ixekizumab [20] ) approved to treat psoriasis. Both the AUC and C max increased proportionally with dose over a range from 0.1 to 10 mg/kg or 50-200 mg for IV and SC administration, respectively. The bioavailability values determined across the two studies were~80% (90% CI: 62-103%) for the 50 mg dose and~73% (90% CI: 46-115%) for the 200 mg dose, respectively, relative to 0.5 and 3 mg/kg IV doses. The bioavailability values have the caveat that they are based on a cross-study comparison and a small number of subjects (in P05661: n = 3 were from the 0.5 mg/kg group and n = 4 were from the 3 mg/kg group). The wide CIs around the geometric mean bioavailability ratios reflect the small sample sizes. The upper limit of the 90% CI exceeding 100% where the comparison is relative to IV administration is likely an artefact of the cross-study comparison and small number of subjects in the IV arms. The observed bioavailability of 73-80% for tildrakizumab was considered favourable for development as it was considered sufficient to provide the necessary tildrakizumab exposure for efficacy. Bioavailability values in the literature for approved monoclonal antibodies are generally 50% or higher [14] .
In the two trials combined, six tildrakizumab-treated subjects had samples which were positive for ADA at post-dose sampling timepoints and two of these subjects were also positive for neutralizing antibodies. There were decreases observed in the terminal half-life of tildrakizumab for these two subjects [10.1 and 13.5 days compared to the range of mean t 1/2 values for each dose level (26.8-32.4 days) when these two subjects were excluded]. There was no apparent correlation of antibody development with dose level.
In both studies, serum IL-22 and total IL-23 levels were undetectable in most subjects. This was likely due to the low levels of these cytokines in healthy subjects relative to the LLOQs of the assays used. Using a more sensitive assay for IL-22 (LLOQ = 0.2 pg/mL), Shukla et al. [21] showed an average concentration of 3.3 pg/mL in healthy subjects. Zaky et al. [22] and Michalak-Stoma et al. [23] observed average IL-23 levels in healthy subjects to be 33 and 46 pg/mL, respectively. Although these observations are higher than the LLOQ of 20 pg/mL used for the IL-23 assay in P05661 and P05776, the assay was likely not sensitive enough to reproducibly measure IL-23 in healthy subjects.
In contrast to IL-22 and IL-23, serum calprotectin was measurable in all subjects. Changes in serum calprotectin did not appear to be treatment-dependent; however, the variability of this parameter may have hampered the ability to detect a treatment response. Therefore, due to variability and assay sensitivity, the effect of tildrakizumab on these three biomarkers of disease activity (IL-22, IL-23, and calprotectin) could not be determined.
Single doses of tildrakizumab 0.1, 0.5, 3 and 10 mg/kg administered IV or single doses of 50 and 200 mg administered SC were safe and well tolerated in healthy adult subjects. The PK profile of tildrakizumab was consistent with that of other human monoclonal antibodies which typically have low CL, a limited volume of distribution, and favourable bioavailability, thus supporting continued development of the SC formulation for use in phase 2 and phase 3 trials.
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